Manufacturing and quality upgrades complete; EU QP GMP inspection cleared
Company joins Bio Europe 2026 to pursue licensing deals and CDMO partnerships
Cumulative third-quarter sales reach 11.66 billion won; seven new biosimilars in development
PanGen, the biopharmaceutical arm of Huons Group, has launched a full-scale push into the European market, leveraging its proprietary platform technology and the regulatory and commercial expertise it has built up across Southeast Asia and the Middle East.
PanGen handles Huons Group's biopharmaceutical business across two areas: a biosimilar business centered on erythropoietin (EPO) and contract development and manufacturing (CDMO) services for biopharmaceuticals.
PanGen's EPO biosimilar is the world's second approved epoetin alfa biosimilar. The company offers one-stop CDMO services built on its proprietary PanGen CHO-TECH™ cell-line technology and a Pharmaceutical Inspection Co-operation Scheme (PIC/S)-compliant good manufacturing practice (GMP) production facility that meets European guidelines.
Mock inspections and EU QP audit cleared, paving way for advanced-market entry
PanGen has been upgrading its GMP facility's manufacturing and quality systems to meet the stringent standards of regulators in advanced markets. After introducing a smart electronic document management system (EDMS) to its quality division last year, the company was selected for the Ministry of SMEs and Startups' smart factory construction support program and completed an advanced laboratory information management system (LIMS) and quality management system (QMS) in March.
The company has also cleared independent quality-reliability checks. PanGen successfully completed two mock inspections through US consulting firms Jeff Yuen & Associates and InterPro QRA.
In April, PanGen was selected for the Korea Health Industry Development Institute's project supporting EPO biosimilar entry into advanced markets. Through consulting with UK-based Scendea, the company completed a gap analysis and reviewed EU qualified person (QP) requirements. It then finished an EU QP GMP inspection with Portugal-based Sifrei, completing all preparatory steps for European market entry.
PanGen has also diversified its overseas business model. While continuing to expand finished-product exports, the company is offering technology transfer arrangements to overseas partners that prefer local production — supplying its active pharmaceutical ingredients so that local manufacturers can produce finished products themselves.
Marketing activity to support the global push has been equally active. PanGen attended the Bio International Convention (BioUSA 2026) in San Diego in June, holding business meetings with more than 60 overseas companies. On Nov. 9, the company participated in Bio Europe 2026 to explore overseas partnerships. Discussions at the event covered EPO biosimilar licensing inquiries as well as the company's antibody biosimilar pipeline and CDMO services.
Cumulative third-quarter sales hit 11.66 billion won; seven new biosimilars on track
PanGen has sustained earnings growth by supplying its EPO biosimilar — a treatment for anemia in chronic kidney disease patients — to domestic and overseas markets alongside its CDMO business. Cumulative sales on a separate financial statement basis through the third quarter reached 11.66 billion won ($8.71 million), up 6.6 percent from the same period last year.
Growth was driven by rising exports to ASEAN countries including Malaysia, the Philippines and Thailand, as well as the launch of full-scale exports to Saudi Arabia and Turkey. The company plans to extend its export reach to Taiwan, Paraguay and Iraq, and further into the Middle East and Africa, while also entering the European market to sustain its sales growth.
Alongside geographic diversification, PanGen is accelerating the expansion of its biosimilar portfolio. Using its proprietary PanGen CHO-TECH™ technology, the company is simultaneously developing seven new biosimilars: ipilimumab (originator brand Yervoy), guselkumab (Tremfya), romosozumab (Evenity), pembrolizumab (Keytruda), benralizumab (Fasenra), risankizumab (Skyrizi) and mepolizumab (Nucala).
Of these, ipilimumab, guselkumab, romosozumab and pembrolizumab have completed cell-line development and are now in process development; PanGen aims to complete process development for ipilimumab, guselkumab and romosozumab by year-end. Benralizumab, risankizumab and mepolizumab remain in the cell-line development stage. The company also plans to expand its CDMO business, using its proprietary core technology to support biosimilar development for other biotech firms and pharmaceutical companies.
"We are expanding our biopharmaceutical business into advanced markets on the strength of our core proprietary technology and accumulated experience," PanGen Chief Executive Yoon Jae-seung said. "We will continue to broaden PanGen's biosimilar competitiveness in the global market."
silverpaper@heraldcorp.com